Figure 4

MTT assays of viability of lung cancer cells to detect dose- and time-dependent responses to cytotoxicity of LPS-BVCM. The LPS-BVCM was added to lung cancer cells in serum-free RPMI 1640 in concentrations of 10%, 25%, 50%, 75%, or 100%. The viability of cancer cells was determined using MTT assays at 12, 24, 36, and 48 h after the LPS-BVCM treatment. The results are presented as the mean values of 4 independent experiments and standard deviations. Significant differences (P < 0.05) are found between the following pairs of groups: (1) At 12 h, 10% LPS-BVCM treatment group vs. 50%, 75%, or 100% LPS-BVCM treatment group and 25% group vs. 100% group; 2) at 24 h, 10% group vs. 50%, 75%, or 100% group; 3) at 36 h, 10%, 25%, 50%, or 75% group vs. 100% group; and 4) at 48 h, 10%, 25%, or 50% group vs. 100 % group and 10% group vs. 75% group.